Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gossamer Bio Inc GOSS

Healthcare Biotechnology
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor... see more

Recent & Breaking News (NDAQ:GOSS)

Gossamer Bio Announces Data Presentations at the Congress of the European Crohn's and Colitis Organisation

Business Wire February 13, 2020

Gossamer Bio Announces Data Presentation at the 2020 Crohn's & Colitis Congress

Business Wire January 23, 2020

Gossamer Bio Announces Participation in Upcoming Investor Conferences

Business Wire November 26, 2019

Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day

Business Wire November 14, 2019

Gossamer Bio Announces Third Quarter 2019 Financial Results

Business Wire November 12, 2019

Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors

Business Wire November 12, 2019

Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019

Business Wire November 11, 2019

Gossamer Bio Announces Data Presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019

Business Wire November 8, 2019

Gossamer Bio Announces Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting

Business Wire November 7, 2019

Gossamer Bio to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 12, 2019

Business Wire November 5, 2019

Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference

Business Wire September 25, 2019

Gossamer Bio Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

Business Wire September 13, 2019

Gossamer Bio Announces Second Quarter 2019 Financial Results

Business Wire August 8, 2019

Gossamer Bio to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019

Business Wire August 5, 2019

Gossamer Bio Announces First Quarter 2019 Financial Results

Business Wire May 14, 2019

Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019

Business Wire May 9, 2019

Gossamer Bio Secures Debt Facility for up to $150 Million

Business Wire May 2, 2019

Gossamer Bio Announces Participation in Bank of America Merrill Lynch Health Care Conference 2019

Business Wire May 1, 2019